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Abstract
Background: Several studies have shown significant associations between manganese superoxide dismutase
(MnSOD) Val16Ala polymorphism and diabetic complications, but this association has not been explored in relation
with chronic kidney disease (CKD) in Type 2 diabetes mellitus (T2DM) patients. Total antioxidant capacity (TAC) level
changes in diabetic condition and may play important role in onset or progression of the disease and its
complications. The present study investigated the association of MnSOD Val16Ala polymorphism and serum TAC
with the risk of CKD in T2DM patients.
Methods: This nested case-control study included 280 type 2 diabetic patients with CKD and 280 age, sex and
diabetes duration-matched control subjects selected from the participants of the Tehran Lipid and Glucose Study.
MnSOD val16Ala (rs4880) SNP was genotyped by the Tetra-Primer ARMS-polymerase chain reaction analysis. Serum
TAC was measured using ferric-reducing antioxidant power assay. Statistical analysis was performed using STATA
statistical package v.12.0 or SPSS (Version 22.0).
Results: The Ala allele of the MnSOD Val16Ala polymorphism was associated with a lower risk of CKD (odds ratio
(OR), 0.55; 95% confidence interval (CI), 0.36–0.84; P = 0.006). Median serum TAC in CKD group was 920 μmol/L and
was significantly lower (p < 0.001) compared to the control group (1045 μmol/L). Using an adjusted conditional
logistic regression, we didn’t observe any significant interaction between MnSOD Val16Ala SNP with quartiles of
serum TAC in relation to CKD.
Conclusion: A significant association was found between the MnSOD Val16Ala polymorphism and CKD, but this
association is not affected by serum TAC level in T2DM patients.
Keywords: Manganese mitochondrial superoxide dismutase (MnSOD), Val16Ala polymorphism, Type 2 diabetes
mellitus, Chronic kidney disease, Total antioxidant capacity (TAC)
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Background
Type 2 diabetes mellitus (T2DM) is the leading cause of
chronic kidney disease (CKD) and an important health
problem with increasing prevalence worldwide [1–3].
Approximately 50% of patients with T2DM suffer from a
moderate-to-severe form of CKD (glomerular filtration
rate (GFR) < 60 ml/min/1.73m2) [2, 3]. CKD and
diabetes are prominent risk factors of cardiovascular
disease and all three qualify as multiple morbidities [4].
In addition, the high treatment cost of diabetes
markedly increases in the presence of chronic
complications such as CKD [5, 6] (Fig. 1).
Oxidative stress is the excess formation and/or insuffi-
cient removal of highly reactive molecules such as react-
ive oxygen species (ROS) and is induced by elevation in
glucose and free fatty acid (FFA) levels. It plays an im-
portant role in the pathogenesis and progression of
T2DM as well as CKD [7, 8]. Mitochondrial respiratory
system impairment increases oxidative stress in T2DM
patients. Normal cell function is inhibited by increased
production of ROS and impairment of the antioxidant
defense mechanism by damage to cell biomolecules.
CKD can become advanced due to a significant increase
in the generation of ROS [4].
Manganese superoxide dismutase (MnSOD) is a key
enzyme in antioxidant defense systems and the most im-
portant member of the SOD family which plays a crucial
role fighting mitochondrial superoxide radicals [9].
There is growing evidence that genetic variants are es-
sential factors in the pathogenesis and development of
DM and its complications [10, 11]. Recently, genome-
wide association studies have identified more than 260
single-nucleotide polymorphisms (SNPs) in relation to
T2DM [12]. It is also generally accepted that there is a
genetic susceptibility to CKD [11]. Previous studies have
identified antioxidant gene variants and risk genotypes
in diabetic populations of different ethnicities [7, 13, 14].
Chromosome 6q25 is the host for the MnSOD gene.
Because they maintain cellular ROS levels, structural
and/or functional SNPs of the MnSOD encoding gene
are prominent fronts in the defense against ROS produc-
tion [4]. A number of polymorphisms in this sequence
have been described, but only the Val16Ala has demon-
strated to have a functional significance [7, 13, 15]. The
SNP rs4880 has been identified at the 16th amino acid
position on the second exon [7, 13, 14, 16].
MnSOD activity is affected by functional Val16Ala
polymorphism through structural changes in the β-sheet
to α-helix in the mitochondrial targeting domain, which
can cause a 30% to 40% increase in MnSOD activity in
mitochondria. The presence of Valine (T allele) leads to
the production of instable mRNA and reduces transport
of the enzyme into the mitochondrial matrix and then
its antioxidant function. This could influence the sever-
ity of oxidative stress related to diabetes and its chronic
complications [9, 16–18]. Given the close link between
CKD and T2DM, it is plausible that T2DM-related anti-
oxidant gene variants and risk genotypes may be in-
volved in the progression of CKD [6, 17].
The cumulative antioxidant capacity of all antioxidants
is calculated as the serum TAC [19, 20]. Oxidative stress
and the delay and prevention of its complications result
from TAC modification. Although not consistent, the
majority of research indicates possible modulation of the
MnSOD Val16Ala SNP by different factors.
The probable interaction between Val16Ala SNP of
the MnSOD gene and health-related factors such as
serum TAC remains an open question [13]. The associ-
ation between MnSOD Val16Ala (rs4880) and the risk of
CKD in DM patients has not yet been clarified. To the
best of our knowledge, this is one of the first studies to
examine the relation of polymorphisms in Iranian
T2DM patients. The present case-control study was de-
signed to investigate the association of MnSOD
Val16Ala polymorphism and serum TAC and their inter-
actions in relation to CKD in T2DM patients.
Methods
Study population
Subjects were participants of Tehran Lipid and Glucose
Study (TLGS), an ongoing population-based cohort
study conducted to determine the risk factors of non-
communicable diseases in a sample of the capital of Iran
residents. The first phase of the TLGS was conducted
from 1999 to 2001 including 15,005 subjects, aged
≥3 years, and follow-up examinations have been con-
ducted every 3 years (2002–2005; 2006–2008; 2008–
2011 and 2011–2014) to identify newly developed
Fig. 1 Median serum total antioxidant capacity (TAC) in CKD group
and non-CKD group. Bars show Median and error bars show 95%CI.
Mann–Whitney U test P value
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diseases. Details of this ongoing cohort study have been
published extensively [21, 22].
The current nested case-control study was based on
World Health Organization diagnostic criteria [23]. A
total of 280 T2DM patients in the fifth phase (2011–
2014) (n = 965) were randomly selected. Inclusion cri-
teria were: having T2DM for at least 5 years; being
≥25 years of age; having no history of cardiovascular,
chronic liver or gastrointestinal disease or cancer; no use
of glucocorticoids; GFR < 60 ml/min/1.73 m2 (defined as
CKD stages 3–5) and; no known history of dialysis or
kidney transplantation. Each case was individually
randomly matched to a control by age (±5 years), sex,
duration of T2DM and a GFR of ˃ 60 ml/min/1.73 m2
(defined as non-CKD stages 1 and 2). A total of 560
T2DM subjects (280 non-CKD controls and 280 CKD
cases) were selected from TLGS phase 5.
The study protocol was approved by the ethical com-
mittee of the Research Institute for Endocrine Sciences,
Shahid Beheshti University of Medical Science, Tehran,
Iran. Written informed consent was obtained from each
subject.
Measurements
Details of data collection in the TLGS have been previ-
ously published. In brief, a standard procedure was used
for evaluation of anthropometric values. The body mass
index (BMI) was calculated. Blood pressure was mea-
sured twice, at baseline and after 15 min of rest and the
mean of the measurements was reported. Demographic
factors were also measured at the study onset using a
standard and validated questionnaire [21].
Laboratory biochemical measurements
A standard colorimetric Jaffe-Kinetic reaction kit (Pars
Azmon; Iran; with inter- and intra-assay CVs of 2.5%
and 1.9%, respectively, and sensitivity of 0.2 mg/dl) was
used to measure serum creatinine (SCr). GFR of each
participant was calculated based on SCr, age, and sex
using the Modification of Diet in Renal Disease (MDRD)
equation: GFR = 186 × (SCr)-1.154 × (Age)-0.203 × (0.742
if female) × (1.210 if black) (24). GFR and SCr are
expressed as ml/min per 1.73 m2 and mg/dl,
respectively, in this equation.
Fasting blood samples were taken after 12–14 h of
overnight fasting. The enzymatic colorimetric method
with glucose oxidase was used to measure the fasting
plasma glucose. Next, 75 g of glucose was administered
orally to measure the 2-h plasma glucose (2 h-PG) and
plasma glucose.
Triglycerides (TG) and high-density lipoprotein chol-
esterol (HDL-C) were measured using enzymatic colori-
metric method and phosphotungstic acid, respectively.
HDL-C measurement was done after precipitation of
apolipoprotein B.
Low-density lipoprotein cholesterol (LDL-C) concen-
trations in samples with serum triglyceride levels of <
400 mg/dl were calculated using Friedewald’s equation.
Analysis was performed using standard kits (Pars
Azmoon; Iran) and a Selectra 2 auto-analyzer (Vital Sci-
entific; The Netherlands). The inter- and intra-assay co-
efficient of variation of all assays was < 5%.
Simultaneous to sample collection, blood analysis was
done in the TLGS research laboratory.
Serum TAC was determined by ferric-reducing anti-
oxidant power assay, using TAC Assay Kit (ZellBio
GmbH, Ulm, Germany; Cat.No.: ZB-TAC-A96/48) with
0.1 mM (100 μmol /L) sensitivity. The assay range was
0.125–2 mM (125–2000 μmol /L).
Genetic analysis
Buffy coats were separated from non-coagulated whole-
blood samples and stored at − 80 °C until processing for
genotyping of the MnSOD Val16Ala (rs4880) poly-
morphism. The proteinase K/salting-out method [24]
was used to extract DNA from the buffy coat. Tetra-
Primer ARMS-PCR assay was administered with minor
changes as described by Ruiz-Sanz et al. [25]. Two pri-
mer pairs were employed to intensify and designate the
genotype of a DNA fragment, including the Ala16Val
SNP in the human MnSOD sequence. The 3′-end of the
allele-specific primers were underlined F1 (forward) 5´-
CACCAGCACTAGCAGCATGT-3′; F2 (forward) 5´-
GCAGGCAGCTGGCTaCGGT-3′; R1 (reverse) 5´-
ACGCCTCCTGGTACTTCTCC-3′ and; R2 (reverse)
5´-CCTGGAGCCCAGATACCCtAAAG-3′. Underlined
lowercase bases denote the incongruence present.
PCR was conducted in a total volume of 40 ml con-
taining 20–40 ng of genomic DNA as the template, 0.
5 mM of each primer, 100 mM of each dNTP, 1.25 mM
of MgCl2, PCR buffer (20 mM Tris-HCl at pH 8.4 and
50 mM KCl), 5% dimethyl sulfoxide (DMSO) and 1.
25 units of DNA polymerase. PCR amplification was
conducted with primary denaturation at 94 °C for 7 min,
followed by 35 cycles of 60 s of denaturation at 94 °C,
20 s of annealing at 60 °C, 30 s of extension at 72 °C and
an additional 7 min extension at 72 °C at the end of the
final cycle. Next, 6 ml of loading buffer was mixed with
a 20-ml aliquot of the PCR products and resolved by
electrophoresis on 1.5% agarose gel. Three distinctive
bands in heterozygotes (514, 366 and 189 bp) were gen-
erated from this procedure and two bands in homozy-
gotes (Val/Val in bands of 514 and 189 bp and Ala/Ala
in bands of 514 and 366 bp). The 514, 366 and 189 bp
fragments were directly sequenced to validate the accur-
acy of genotype scoring using tetra-primer ARMS-PCR.
Ten per cent of the samples were sequenced by the
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Pasteur Institute of Iran, using ABI Genetic Analyzer
3130 and confirmed the accuracy of the MnSOD geno-
typing methods.
Statistical analysis
All continuous data with a normal distribution are
expressed as mean ± SD. Skewed parameters are
expressed as median (25–75%), and categorical variables
are expressed as frequency and percentage. Differences
in continuous variables were assessed using a t-test or
non-parametric Mann–Whitney U test. Differences in
categorical variables were assessed using the chi-square
test. Allele frequency and genotype frequency were cal-
culated using Power Marker v.3.25 [26]. The Hardy-
Weinberg equilibrium, which indicates the absence of
discrepancy between genotype and allele frequencies,
was checked using the chi-square statistic. A multivari-
ate logistic regression model was used to estimate the
odds ratios (ORs) and the corresponding 95% confidence
intervals (CIs) of CKD-related factors.
To calculate the interaction of the MnSOD Val16Ala
SNP with quartiles of serum TAC in relation to CKD,
conditional logistic regression was used. TAC values
were categorized into quartiles computed among con-
trols. The results were two likelihood scores with and
without the interaction terms. The likelihood ratio test
was used to determine the p-value for interaction.
To generate ORs for CKD, conditional logistic regres-
sion was used in individual carriers or non-carriers of
the risk allele (Ala/Ala+Ala/Val and Val/Val) across
quartiles of serum TAC (Q1-Q4). As the reference
group, the lowest quartile of TAC and the homozygote
group (Val/Val) were explored. CKD-associated vari-
ables, including BMI, energy intake, total cholesterol,
LDL-cholesterol, triglycerides, systolic and diastolic
blood pressure, smoking status and medications (anti-
diabetic medication (oral and insulin), lipid drugs and
anti-hypertensive drugs (diuretic drugs, beta-blockers,
ACE-inhibitors, Calcium channel blockers, Angiotensin
II receptor antagonists and vasodilator drugs)) included
adjusted ORs. The age, sex and duration of T2DM were
not adjusted as they were matched at the beginning of
the study. Two-tailed p-values of < 0.05 were considered
statistically significant. Statistical analysis was performed
using STATA v.14.0 statistical package or SPSS (ver. 22.
0; IBM).
Results
Table 1 summarizes the general characteristics of the
case and control participants. The non-CKD subjects
had higher GFR and lower Cr values than the CKD par-
ticipants. There were no significant differences in all
other characteristics between groups. The median serum
TAC in the CKD group of patients was 920 μmol/l and
was significantly lower (p < 0.001) than for the non-CKD
group (1045 μmol/l).
Association of MnSOD Val16Ala (rs4880) polymorphism
with CKD
The rs4880 polymorphism was in the Hardy–Weinberg
equilibrium. In non-CKD subjects, the frequency of the
Ala allele was 47.12% and in the CKD cases it was 37.4%
(p = 0.004). The genotype frequencies for the control
and case groups were as follows: Val/Val: 72.5% and 63.
2%, respectively; Ala/Ala+Ala/Val: 20.4% and 30.4%, re-
spectively (p = 0.001; Table 2). The Ala allele of the
Val16Ala polymorphism is associated with a lower risk
of CKD (odds ratio (OR) of 0.53; 95% confidence inter-
val (CI) of 0.35–0.82; p = 0.004). Comparing homo and
heterozygote genotypes, Ala homozygote genotype (Ala/
Ala) indicate a lower risk of CKD compared to the Val
homozygote genotype reference group (OR: 0.30; 95%
CI: 0.16–0.57; p = 0.001; Table 2). Under the dominant
genetic model, Ala allele carriers (Ala/Ala+Ala/Val) indi-
cate a lower risk of CKD compared to the Val homozy-
gote genotype reference group (OR: 0.55; 95% CI: 0.36–
0.84; p = 0.006; Table 2).
Interaction of MnSOD Val16Ala (rs4880) with serum TAC
in relation to CKD
A possible interaction between MnSOD Val16Ala poly-
morphism and serum TAC for the risk of CKD was
tested for the T2DM patients. Table 3 presents the ad-
justed OR for CKD risk based on quartile classification
of serum TAC by the dominant model of MnSOD
Val16Ala genotypes. Among Ala allele carriers (Ala/Ala
+Ala/Val), a decreased risk of CKD was associated with
being in the highest quartile of serum TAC over those in
the lowest quartile (p-trend = 0.002). No significant asso-
ciation was found between serum TAC and risk of CKD
(p-trend = 0.055) in the Val/Val genotype carriers of
MnSOD Val16Ala (rs4880; Table 3). No significant inter-
action was observed between the MnSOD gene Val16Ala
polymorphism and serum TAC in relation to CKD in
T2DM patients.
Discussion
Val16Ala (rs4880) is the most studied MnSOD gene
polymorphism for diseases related to including T2DM
and its kidney complications [4, 17, 18]. MnSOD
Val16Ala polymorphism affects the processing efficiency
of the antioxidant enzyme by causing changes in its con-
formation leading to less efficient mitochondrial trans-
portation of the Val form, which may reduce the
MnSOD activity and concentration in the mitochondria
and results in inefficient targeting of MnSOD. Lowered
resistance to oxidative stress and a decrease and mistar-
geting of MnSOD activity has been observed more often
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in homozygous Val/Val than in patients with other
MnSOD variants [27, 28]. T2DM patients that are Val
carriers can develop hyperglycemia and activation of
stress-sensitive signaling pathways by reactive metabo-
lites causing oxidative stress [7]. ROS overproduction
and increased oxidative stress have been shown to
participate actively in the pathogenesis and progression
of T2DM renal complications and CKD [29–31].
The purpose of this study was to clarify the relation-
ship between MnSOD Val16Ala polymorphism and
serum TAC in patients with a risk of CKD in T2DM pa-
tients. The interaction of the serum TAC level and
Table 2 Adjusted OR for the CKD according to genotype, dominant model and allele of MnSOD Val16Ala genotype
Polymorphism Genotype CKD N (%) Non-CKD N (%) OR (95% CI) P Value
MnSOD Val16Ala (rs4880) Genotype
Val/Val 85 (30.4%) 57 (20.4%) 1 (ref.)
Ala/Val 158 (56.4%) 161 (57.5%) 0.65 (0.44–0.98) 0.041
Ala/Ala 19 (6.8%) 42 (15%) 0.30 (0.16–0.57) 0.001
Dominant Genotype Model
Val/Val 177 (63.2%) 203 (72.5%) 1 (ref.) 0.006
Ala/Ala + Ala/Val 85 (30.4%) 57 (20.4%) 0.55 (0.36–0.84)
Allele
Val 328 (62.6%) 275 (52.88%) 1 (ref.) 0.004
Ala 196 (37.4%) 245 (47.12%) 0.53 (0.35–0.82)
ORs (odds ratios and 95% confidence intervals) were calculated using multivariate logistic regression analysis adjusted for BMI, energy intake, total Cholesterol,
LDL-Cholesterol, triglyceride, Systolic and Diastolic blood pressure, smoking status and medication; CKD chronic kidney disease. CKD was defined as estimated
glomerular filtration rate < 60 ml/min/1.73 m2. eGFR estimated glomerular filtration rate, MnSOD Manganese superoxide dismutase
Table 1 Comparison of characteristics between subjects with and without CKD (n = 560)
CKD (n = 280) Non-CKD (n = 280) P value
GFR (ml/min/1.73m2) 54.03 (12.81) 67.54 (6.45) <0.001
Age (y) 64 (12.50) 63 (13.75) 0.154
Sex (Male/Female) 105/175 105/175 –
Duration of diabetes (y) 11.99 (6.4) 11.87 (4.72) 0.417
Body mass index (kg/m2) 28.72 (9.9) 28.47 (3.88) 0.554
Systolic blood pressure (mmHg) 13 (3) 13 (3) 0.203
Diastolic blood pressure (mmHg) 80 (18) 79 (20) 0.581
Use of anti-hypertensive drugs 157 (56.5%) 124 (44.9%) 0.057
Fasting plasma glucose (mg/dl) 143 (23) 136 (38) 0.078
2 h-PG (mg/dl) 227.16 ± 89.431 209.09 ± 91.73 0.896
Use of glucose-lowering drugs 201 (72.3%) 207 (74.7%) 0.510
Total cholesterol (mg/dl) 184 (59) 187.5 (41) 0.702
HDL cholesterol (mg/dl) 47 (12) 46 (20) 0.914
LDL cholesterol (mg/dl) 102.8 (49) 106.8 (43) 0.426
Triglyceride (mg/dl) 154.5 (124) 148 (127) 0.347
Use of lipid-lowering drugs 125 (45%) 112 (40.4%) 0.459
Creatinine (mg/dl) 1.2 (0) 1 (0) <0.001
FRAP (μmol/L) 920 (252.5) 1045 (217.5) <0.001
Current or pervious smoking 19 (6.8%) 14 (5%) 0.375
Hyperlipidemia 48 (17.1%) 47 (16.8%) 0.514
Hypertension 32 (11.4%) 48 (17.1%) 0.138
Obesity (BMI≥ 30) 103 (36.8%) 104 (37.1%) 0.986
Results are expressed as median (IQR), n (%) or mean ± SD. Mann–Whitney U test, t-test or Chi square test P value. CKD = chronic kidney disease. CKD was defined
as estimated glomerular filtration rate < 60 ml/min/1.73 m2. GFR glomerular filtration rate, HDL high density lipoprotein, LDL low density lipoprotein, FRAP Ferric
Reducing Ability of Plasma. The values given in italic in P-value column are significant
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genetic variants of rs4880 in relation to CKD risk was
also examined. The association of MnSOD val16Ala
polymorphism has been shown to decrease the risk of
CKD and GFR [17, 32–34]. The present study is the first
to examine the role of rs4880 in the risk of CKD in
T2DM patients and the effect of its interaction with
TAC level.
The results show that patients with the Ala/Ala+Ala/
Val genotype exhibited lower CKD risk than those with
the Val/Val genotype. The Ala allele resulted in higher
MnSOD level and increased degradation of ROS, redu-
cing the oxidative stress burden in the carriers [35]. Des-
pite inconsistencies [33, 34], this is in line with results
from previous studies which have suggested that the Ala
allele carriers have lower risk of decline in kidney func-
tion and progression of CKD [17, 32]. Discrepancies
among available studies might be explained by differ-
ences in disease status and the ethnic backgrounds of
the study populations. Studies which are consistent with
the present study have reported a relationship between
functional impairment of the MnSOD gene with in-
creased risk of renal complications in T2DM patients
such as diabetic albuminuria [36, 37] and nephropathy
[18, 36, 38], the leading causes of CKD [17, 39].
The serum TAC level decreases significantly in T2DM
patients and it has been suggested that the risk of T2DM
is lower in subjects with higher serum TAC levels [4, 8,
40, 41]. Low TAC levels associated with hyperglycemia
and impaired metabolic status in these patients could ex-
acerbate oxidative stress and increase damage [42, 43].
The current study found a significant decrease in total
antioxidant level among T2DM CKD cases at 920 (450–
1880 μmol/l) compared to the T2DM non-CKD controls
at 1045 (460–1740 μmol/l). Serum total antioxidant activ-
ity against oxidative stress to decrease and control damage
could result in the decreased TAC level among CKD sub-
jects. Decreases in TAC level due to abnormal lipid perox-
idation could also accelerate glomerular damage [41].
Studies have shown that environmental factors poten-
tially can modulate the genetic association between
MnSOD Val16Ala and the risk of developing disease or
dysfunction which interferes with the redox balance [4,
13]. The effect of the interaction between this MnSOD
SNP and antioxidant status on cancer risk has been re-
ported for cervical and breast cancer [13, 44, 45].
An increase in the quartile of the serum TAC partici-
pants with the Ala/Ala+Ala/Val genotype was found to
decrease CKD risk. However, in T2DM patients, there
was no significant interaction between MnSOD Val16Ala
SNP and the TAC level in relation to CKD. More studies
are needed to investigate the role of factors directly re-
lated to oxidative stress, such as serum TAC in T2DM
complications and CKD- formation and progression.
The strengths of the current study were the sampling
of the prospective TLGS study participants for long-
term follow-up, individually-matching controls by age,
sex and diabetes duration, the drug history of partici-
pants and extensive adjustment for potential CKD con-
founders. Although limited potential for selection bias is
of a concern in nested case control studies, applying in-
dividual matching by our study inclusion criteria in our
sampling, we tried to minimize it. One other limitation
is the lack of generalization due to selection of the popu-
lation from TLGS participants.
Conclusion
The findings demonstrate that the MnSOD Val16Ala
polymorphism and serum TAC level are associated with
CKD independent of other known risk factors in type 2
diabetic patients. The Ala allele appears to provide re-
sistance to CKD in T2DM patients. Decreased median
serum TAC was observed in the CKD patients. No sig-
nificant interaction was found between MnSOD
Val16Ala polymorphism and serum TAC in relation to
CKD.
Table 3 Adjusted OR for the CKD according to quartile (Q) classification of TAC by the genotype and dominant model of MnSOD
Val16Ala genotype
MnSOD Val16Ala (rs4880) OR (95% CI) quartiles P for
trend
P for
interactionQ1 Q2 Q3 Q4
Genotype
Val/Val (n = 142) 1 (ref.) 1.79 (0.66–4.83) 2.02 (0.71–5.72) 0.97 (0.36–2.6) 0.055 0.082
Ala/Val (n = 319) 2.33 (1.18–4.59) 3.48 (1.83–6.63) 6.38 (3.33–13.2) 4.47 (2.64–7.58) 0.063
Ala/Ala (n = 61) 1.58 (0.33–7.55) 4.75 (0.99–22.67) 4.75 (0.91–24.55) 1.78 (1.06–2.99) 0.133
Dominant Model
Val/Val (n = 142) 1 (ref.) 1.79 (0.66–4.83) 2.02 (0.71–5.72) 0.97 (0.36–2.6) 0.055 0.254
Ala/Ala+Ala/Val (n = 380) 1.98 (0.82–4.78) 1.13 (0.48–2.65) 0.66 (0.28–1.59) 0.3 (0.12–0.72) 0.002
ORs (odds ratios and 95% confidence intervals) were calculated using the conditional logistic regression model, adjusted for BMI, energy intake, total Cholesterol,
LDL-Cholesterol, triglyceride, Systolic and Diastolic blood pressure, smoking status and medication. The lowest quartile of serum TAC and homozygote genotype
with major allele (Val/Val) were used as the reference group
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Abbreviation
2 h-PG: 2-h plasma glucose; BMI: body mass index; CI: confidence interval;
CKD: Chronic kidney disease; DMSO: Dimethyl sulfoxide; FFA: free fatty acid;
GFR: glomerular filtration rate; HDL-C: high-density lipoprotein cholesterol;
LDL-C: Low-density lipoprotein cholesterol; MDRD: Modification of Diet in
Renal Disease; MnSOD: Manganese superoxide dismutase; OR: odds ratio;
ROS: reactive oxygen species; SCr: serum creatinine; SNPs: single-nucleotide
polymorphisms; T2DM: Type 2 diabetes mellitus; TAC: Total antioxidant
capacity; TG: Triglycerides; TLGS: Tehran Lipid and Glucose Study
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